Inactive Instrument
Antibe Therapeutics Inc Stock Toronto S.E.
Stocks
ATE
CA0370251039
Biotechnology & Medical Research
OTC Markets Traded| 24-07-03 | Antibe Therapeutics : NOTICE TO CLAIMANTS OF ANTIBE THERAPEUTICS INC. (“ANTIBE”) | PU |
| 24-04-24 | Antibe Announces Appointment of Receiver | BU |
| 24-04-22 | ANTIBE PROVIDES UPDATE ON CCAA PROCEEDINGS | AQ |
| 24-04-19 | Antibe Provides Update on CCAA Proceedings | BU |
| 24-04-16 | Antibe Announces TSX Delisting Review | BU |
| Manager | Title | Age | Since |
|---|---|---|---|
Alain Wilson
DFI | Director of Finance/CFO | - | 2015-11-30 |
David Vaughan
CTO | Chief Tech/Sci/R&D Officer | 76 | - |
| Investor Relations Contact | 50 | - |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | +4.17% | - | - | 11.47M | |
| +0.24% | -1.54% | +52.85% | +71.85% | 53.83B | |
| -7.17% | -4.39% | +42.72% | +73.32% | 52.1B | |
| +0.80% | -6.31% | +5.62% | +417.78% | 23.48B | |
| -0.09% | -0.01% | -16.85% | -15.41% | 23.13B | |
| -5.95% | -2.58% | +29.53% | -9.47% | 19.36B | |
| -1.14% | +0.03% | +31.67% | -30.65% | 17.56B | |
| -5.16% | -7.00% | +168.44% | +314.96% | 15.2B | |
| -6.91% | -5.83% | +25.17% | +644.30% | 14.83B | |
| +0.43% | -1.03% | +25.75% | +189.74% | 14.06B | |
| Average | -2.50% | -2.62% | +40.54% | +184.05% | 25.95B | |
| Weighted average by Cap. | -2.80% | -2.36% | +39.55% | +143.13% |
Employees
-
